- Home
- DATS vs NLSP Comparison
DATS vs NLSP Comparison
Compare DATS & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- NLSP
- Stock Information
- Founded
- DATS 2014
- NLSP 2015
- Country
- DATS United States
- NLSP Switzerland
- Employees
- DATS N/A
- NLSP N/A
- Industry
- DATS Computer Software: Prepackaged Software
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- DATS Technology
- NLSP Health Care
- Exchange
- DATS Nasdaq
- NLSP Nasdaq
- Market Cap
- DATS 10.4M
- NLSP 12.4M
- IPO Year
- DATS 2021
- NLSP 2021
- Fundamental
- Price
- DATS $2.60
- NLSP $2.68
- Analyst Decision
- DATS
- NLSP
- Analyst Count
- DATS 0
- NLSP 0
- Target Price
- DATS N/A
- NLSP N/A
- AVG Volume (30 Days)
- DATS 373.1K
- NLSP 325.4K
- Earning Date
- DATS 08-13-2025
- NLSP 07-07-2025
- Dividend Yield
- DATS N/A
- NLSP N/A
- EPS Growth
- DATS N/A
- NLSP N/A
- EPS
- DATS N/A
- NLSP N/A
- Revenue
- DATS $388.00
- NLSP N/A
- Revenue This Year
- DATS N/A
- NLSP N/A
- Revenue Next Year
- DATS N/A
- NLSP N/A
- P/E Ratio
- DATS N/A
- NLSP N/A
- Revenue Growth
- DATS N/A
- NLSP N/A
- 52 Week Low
- DATS $1.01
- NLSP $1.30
- 52 Week High
- DATS $9.34
- NLSP $16.00
- Technical
- Relative Strength Index (RSI)
- DATS 48.99
- NLSP 62.59
- Support Level
- DATS $2.54
- NLSP $2.19
- Resistance Level
- DATS $2.80
- NLSP $2.54
- Average True Range (ATR)
- DATS 0.26
- NLSP 0.19
- MACD
- DATS -0.02
- NLSP -0.01
- Stochastic Oscillator
- DATS 12.39
- NLSP 57.89
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.